Carcinoma, Transitional Cell
Recent clinical, regulatory, research and industry developments relating to this disease.
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Immuno-Oncology Advances in Genitourinary Cancers.
Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression.
Mechanisms of Resistance to Antibody-Drug Conjugates.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q4 2029.
Clinical MilestonesViewHide
- 2026-07-13FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic AlterationResults expected Q4 2029
- 2026-07-13ClinicalFORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic AlterationResults expected Q4 2029
- 2026-02-20ClinicalA Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial CancerTerminated
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Javlor is indicated in monotherapy for the treatment of adult patients with advanced or m… (2009)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Carcinoma, Transitional Cell16
- Urinary Bladder Neoplasms14
- Antibodies, Monoclonal3
- Immunoconjugates3
- Antibodies, Monoclonal, Humanized2
- Carcinoma, Non-Small-Cell Lung2
- Head and Neck Neoplasms2
- Kidney Neoplasms2
Leading journals6
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology4
- Clinical cancer research : an official journal of the American Association for Cancer Research3
- The New England journal of medicine3
- Annals of oncology : official journal of the European Society for Medical Oncology2
- American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting1
- Cancer1
Leading researchers8
- Gupta S4
- Loriot Y3
- Petrylak DP3
- Powles T3
- Rosenberg JE3
- Shariat SF3
- Agarwal N2
- Bajorin DF2
Affiliations (unnormalised)6
- Memorial Sloan Kettering Cancer Center3
- Cleveland Clinic Taussig Cancer Institute2
- Massachusetts General Hospital2
- Weill Cornell Medical College2
- Yale Cancer Center2
- Abramson Cancer Center1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Carcinoma, transitional cell is a malignant neoplasm arising from transitional epithelial cells. It occurs chiefly in the urinary bladder, and also in the ureters and renal pelvis.
The supplied grounding does not identify a specific cause or aetiology. It does note that the disease has been studied in relation to secondary disease and genetics, but no causal mechanism is stated.
The grounding supports a malignant epithelial origin, with pathology and genetics as studied aspects. Review material indicates that urothelial carcinoma is treated with immune checkpoint inhibitors and antibody-drug conjugates, implying biologic relevance of immune evasion and target-antigen expression, but it does not provide a full disease mechanism.
The supplied grounding does not support specific risk factors for this disease.
The grounding supports treatment with immune checkpoint inhibitors and antibody-drug conjugates at the modality or drug-class level. Co-studied agents include pembrolizumab, enfortumab vedotin, and sacituzumab govitecan, and cisplatin is also represented among studied therapies. The literature also discusses monoclonal antibodies and humanized monoclonal antibodies as relevant therapeutic classes.
AI-generated summary grounded in MeSH and 4 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.